Reva Medical (ASX:RVA) has expanded its commercial operations into Switzerland, the company said today, with the first implant of its Fantom bioresorbable scaffold.
The scaffold is made from Reva’s tyrosine-derived, radiopaque polymer, rendering Fantom visible under fluoroscopy – a characteristic that is unique to Reva’s product.
Get the full story at our sister site, Drug Delivery Business News.